PharmiWeb.com - Global Pharma News & Resources
26-Mar-2019

CO.DON AG: Operational boost for Executive Board

DGAP-News: CO.DON AG / Key word(s): Personnel

26.03.2019 / 10:00
The issuer is solely responsible for the content of this announcement.


CO.DON AG: Operational boost for Executive Board

+ Manager with international marketing and sales experience

+ Continuation of successful commercial and international strategy

Berlin / Teltow, 26 March 2019 - The Supervisory Board has appointed Tilmann Bur (54) as an additional member of the Executive Board of CO.DON AG with effect from 1 June 2019. He will strengthen the overall leadership of CO.DON AG and assume responsibility for marketing and sales. Ralf Jakobs continues to lead all the other business segments and acts as the spokesman of the Executive Board.

Professor Hans Bauerfeind, Supervisory Board Chairman of CO.DON AG. "In Tilmann Bur we have been able to attract a manager with experience of the national and international pharma business and are convinced that in close collaboration with Ralf Jakobs, his colleague on the Executive Board, he will lead the company in the internationalisation of its business and the ongoing development of mutually beneficial working relationships with customers.

Mr Bur is an internationally experienced sales and marketing manager, who has worked in the medical devices and biotech sector for 19 years, particularly in the hospital market, with a focus on Germany and Europe. He has wide-ranging experience of professional relationship management with decision-makers, especially in orthopaedic and surgical clinics, as well as in building and leading national and international sales organisations and wholesale networks. He knows the purchasing structures in the European hospital market and is an expert in KOL management and clinical marketing.

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Mei├čner, M.A.

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de



26.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CO.DON AG
Warthestra├če 21
14513 Teltow
Germany
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

Editor Details

Last Updated: 26-Mar-2019